EUVIMEDEUVIMED entdecken
Crossref

Utilization of Circulating Tumor DNA in the Surveillance Setting

Jennifer N Gibbs, Paul S Dale, Andrew L Weatherall

The American Surgeon™ · 2023-09 · 89 (9) · 3799-3802

DOI: 10.1177/00031348231161750 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 05.07.2023. Verfasst von Jennifer N Gibbs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Navicent, Macon, GA, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

National guidelines give recommendations regarding cancer surveillance follow-up. In many early staged cancers radiographic imaging and labs are not routinely recommended unless patients are symptomatic. This can cause a gap in care because commonly when patients present symptomatically, they have progressed and transitioned to later-stage cancer. This study demonstrates how circulating tumor DNA (ctDNA) can be used alongside current guidelines to help screen patients for recurrence in the surveillance setting.

Methods

A retrospective chart review was performed. Fifty-five charts were reviewed of patients who received ctDNA testing drawn in follow-up after their primary tumor or metastatic disease was rendered surgically or radiographically disease-free. A customized signature profile, using the sixteen most prevalent genomic markers from a patient’s primary tumor or biopsy, is developed by whole-exome sequencing. Serial blood draws are then drawn to assess for specific DNA markers using polymerase chain reaction (PCR) assays.

Results

Fifty-five charts were reviewed in patients who had stage I-III breast, pancreatic, melanoma, and colorectal cancer. Of the fifty-five, a total of seven had a positive test. Of the seven positive tests, six patients were found to have recurrent/metastatic disease. One positive test was performed four weeks postoperatively but by the second draw ten weeks postoperatively had non-detectable ctDNA. The remaining forty-eight patients had non-detectable ctDNA levels and to date have not had any evidence of recurrence based on standard follow-up guidelines.

Conclusion

The utilization of ctDNA in the surveillance setting can be used to help detect recurrence in the surveillance setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplasmsHumansRetrospective StudiesBiomarkers, TumorNeoplasm Recurrence, Local

Stichwörter der Autor:innen

cancer surveillancecirculating tumor DNA

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Atrium Health Navicent, Macon, GA, USA.
  • Atrium Health Navicent The Medical Center, Macon, GA, USA.

Zitieren

APA

Gibbs, J. N., Dale, P. S., & Weatherall, A. L. (2023). Utilization of Circulating Tumor DNA in the Surveillance Setting. The American Surgeon™, 89(9), 3799-3802. https://doi.org/10.1177/00031348231161750

Vancouver

Gibbs JN, Dale PS, Weatherall AL. Utilization of Circulating Tumor DNA in the Surveillance Setting. The American Surgeon™. 2023;89(9):3799-3802. doi:10.1177/00031348231161750

BibTeX
@article{Gibbs2023,
  author = {Gibbs, Jennifer N and Dale, Paul S and Weatherall, Andrew L},
  title = {Utilization of Circulating Tumor DNA in the Surveillance Setting},
  journal = {The American Surgeon™},
  year = {2023},
  volume = {89},
  number = {9},
  pages = {3799--3802},
  doi = {10.1177/00031348231161750}
}
Kostenlos starten →